VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma

Zhou, Quan; Zhu, Yong; Deng, Zhihong; Long, Haitao; Zhang, Shaoxian; Chen, Xingli

doi:10.1016/j.suronc.2009.09.002

Cited by 39 publications

(36 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings are reported by several authors [4,21,25,26]. We found no statistically significant decline in serum VEGF concentration following surgery in osteosarcoma patients (p00.480) but the overall trend of decline in serum VEGF level prechemotherapy-postchemotherapy-postsurgery was statistically significant (p00.005).…”

Section: Discussionsupporting

confidence: 90%

Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

Rastogi

Kumar

Sankineani

et al. 2012

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

Rastogi

Kumar

Sankineani

et al. 2012

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

“…In addition, our data indicated that the levels of EMMPRIN/CD147 expression were significantly associated with the pathological degree of osteosarcoma, but not with age, tumor size, location, gender, treatment or histological subtype. These findings are consistent with a recent study (33) and further support the notion that the pathological stage and EMMPRIN/CD147 expression may be ideal prognostic factors for human osteosarcoma.…”

Section: Discussionsupporting

confidence: 92%

“…The cellular expression of EMMPRIN/CD147 in surgical tumor tissues from patients was detected by immunohistochemistry analysis, as described previously (32,33) using the Streptavidin-Avidin-BiotinPeroxidase Complex (SABC). The specimen tissue sections at 4 µm were treated with 3% H 2 O 2 for 10 min at room temperature.…”

Section: Methodsmentioning

confidence: 99%

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Lü

Kim

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Recent studies have shown that extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) promotes adhesion, invasion and metastasis of malignant tumor cells. The aim of this study was to investigate the impact of EMMPRIN/CD147 expression on prognosis and its correlation with clinicopathological characteristics in patients with osteosarcoma. The expression of EMMPRIN/CD147 in 55 surgical specimens from patients with osteosarcoma at stage IIA or above, 15 non-tumor rib bone tissues, three human osteosarcoma cell lines (Saos-2, U-2OS and MG-63), the human osteoblast cell line HOB and the malignant melanoma cell line A375 were examined by immunohistochemistry, western blot analysis and ELISA, respectively. The potential association of the levels of EMMPRIN/CD147 expression in osteosarcoma specimens with the overall survival of patients was statistically analyzed. We found that the EMMPRIN/CD147 was expressed in 45 out of 55 osteosarcomas, with immunoreactivity primarily within the membrane and cytoplasm of tumor cells, but not in the non-tumor bone tissues. We also observed that EMMPRIN/CD147 was expressed in Saos-2, U-2OS, MG-63 and A375, but not in HOB cells. The levels of EMMPRIN/CD147 expression correlated positively with the pathological degree of osteosarcoma and negatively with the survival period of patients with osteosarcoma. The expression of EMMPRIN/CD147 is a potential factor in the development and prognosis of osteosarcoma and may be a novel therapeutic target of human osteosarcoma.

show abstract

“…Angiogenesis is considered playing a central role in tumor unrestrained growth and development of metastases (18). We tested the effet of sinomenine on anti-vasculogenic activity.…”

Section: Anti-vasculogenic Activity In Osteosarcoma Of Sinomeninementioning

confidence: 99%

Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway

Xie

Ren

Lin

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Osteosarcoma is the most common primary malignant tumor of the bone. The long-term survivals continue to be unsatisfactory for patients with metastatic and recurrent disease. Metastasis is still a severe challenge in osteosarcoma treatment. Sinomenine, an alkaloid from traditional Chinese medicine, has been proved to possess potent antitumor and anti-invasion effect on various cancers. However, the effect of sinomenine on human osteosarcoma and the underlying mechanisms remains unknown. We report here that sinomenine inhibited proliferation by inducing S phase arrest and suppressing the clone formation. Significant inhibitory effects were found in invasion and metastasis in osteosarcoma, but little cytotoxicity was observed in tested concentrations. Exposure to sinomenine resulted in suppression of invasion and migration in osteosarcoma cells as well as tube formation ability in the human umbilical vein endothelial cells (HUVEC) and U 2 OS cells. Furthermore, it demonstrated that CXCR4 played a key role contributing to invasion in osteosarcoma which is considered to be a core target site in sinomenine treatment. Sinomenine inhibited invasion by suppressing CXCR4 and STAT3 phosphorylation then downregulating the expression of MMP-2, MMP-9, RANKL, VEGF downstream. In addition, then RANKL-mediated bone destruction stimulated by osteoclastogenesis and VEGF-related neovascularization were restrained. Importantly, in vivo, sinomenine suppressed proliferation, osteoclastogenesis and bone destruction. Through these various comprehensive means, sinomenine inhibits metastasis in osteosarcoma. Taken together, our results revealed that sinomenine caused S phase arrest, inhibited invasion and metastasis via suppressing the CXCR4-STAT3 pathway and then osteoclastogenesis-mediated bone destruction and neovascularization in osteosarcoma. Sinomenine is therefore a promising adjuvant agent for metastasis control in osteosarcoma.

show abstract

VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma

Cited by 39 publications

References 27 publications

Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway

Contact Info

Product

Resources

About